You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Validating the MicroKine Assay for Use in Identifying Personalized Precision Therapies for Pediatric Sepsis

    SBC: PreDxion Bio, Inc.            Topic: NICHD

    Project Summary Abstract PreDxion BioLLC is a precision medicine diagnostic company developing an assay platformthe MicroKineassay cartridge and readerthat measures serum proteins in less thanminutes from a single drop of bloodThis fastactionable information allows for the first time individualized precision medicine aimed at reducing pediatric morbidity and mortality in pediatric sepsisthe number ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Retinal eye-tracking for the prognosis and monitoring of multiple sclerosis

    SBC: C. Light Technologies, Inc.            Topic: NINDS

    Abstract The goal of this project is to validate an innovativehighly sensitive retinal eye tracking technologythe tracking scanning laser ophthalmoscopeTSLOas a prognostic and monitoring tool for neurodegenerative disordersnamely multiple sclerosisMSThe applications of effective treatments for multiple sclerosis are constrained bythe absence of methods for early detection andquantitativehighly sen ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics

    SBC: SAB Capra LLC            Topic: NIAID

    Project Summary A research plan is proposed to engineer goats that produce fully human immunoglobulinThese animals will be evaluated as a candidate platform system for production of both targeted therapeutic immunoglobulin as well as reagent antibodies for standards and controls of serological assays of human clinical samplesPrevious studies have demonstrated that ungulates such as cattle can prod ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  5. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  6. Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury

    SBC: Mitovation, Inc.            Topic: 101

    Neonatal hypoxia ischemia is a known cause of cerebral damage resulting from inadequate blood flow and or oxygen delivery to the infant brain beforeduringor after birthThe occurrence among hospital deliveries isperfull term births with a drastic increase among premature newbornsThe deficit in oxygen delivery to the brain results in extensive damage and severe disabilitiesRestoration of blood flow ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Formation and Structural Property Relationships of a Tetracalcium Phosphate Bone Adhesive Biomaterial

    SBC: RevBio, Inc            Topic: NIA

    Project Abstract Approximatelyof all fractures occur in the small bones of the wristshands and feetamounting to more thanmillion annuallyConsidering functional losses associated with the locations of these injuriesproper reduction and fixation is critical to ensure optimal rehabilitation and recoveryComplex injuries that include irreducible fractures or segmental bone loss require operative fixati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Automated preparation of single-cells and nuclei from solid tissues

    SBC: S2 GENOMICS, INC            Topic: 172

    Project Summary AbstractThis project designsdevelopsand automates a novel system to process solid tissue into single cellssingle nucleiand high molecular weight DNA using disposable cartridges without user interventionThe system will support downstream single cell RNA or DNA sequencingsingle nuclei RNA or DNA sequencingand long read sequencers and optical mappingThe long term goal of the project i ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINE

    SBC: Sunomix Therapeutics            Topic: NIAID

    ABSTRACTA staggering number of overbillion individuals worldwide are currently infected with herpes simplex virus typeand or typeHSVandampHSVwhich cause genital herpesMost HSV seropositive individuals are asymptomaticASYMPand never have any recurrent herpetic diseaseIn contrasta small proportion is symptomaticSYMPwith frequentoften lifelong bouts of recurrent herpetic diseasea result of reactivati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke

    SBC: BioTime, Inc.            Topic: 100

    ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government